A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli

Wyeth is now a wholly owned subsidiary of Pfizer256 enrolled

Overview

To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, post- intervention in the selected medical centres

This is post-interventional study to follow the acquisition rate of ESBP producing E. coli or K. pneumoniae at the sites involved in a previous interventional study.

Study Type

OBSERVATIONAL

Enrollment

256

Conditions

Infection

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion 1. All patients admitted or transferred to ICU/burn unit. 2. Patients of either sex, 18 years of age or older. Exclusion Patients were excluded if they had underlying conditions or diseases that were ultimately fatal within 48 hours

Locations (2)

Unnamed facility

Miaoli County, Taiwan

Unnamed facility

Taichung, Taiwan

Outcomes

Primary Outcomes

The acquisition rate of ESBL producing E. coli or K. pneumoniae at the end of surveillance phase

Time frame: 48hours

Secondary Outcomes

The infection rate due to ESBL producing E. coli, or due to K. pneumoniae at the end of surveillance phase

Time frame: 48hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.